Electromed Sets Virtual Annual Meeting, Board Backs All Proposals

Ticker: ELMD · Form: DEF 14A · Filed: Sep 30, 2025 · CIK: 1488917

Electromed, Inc. DEF 14A Filing Summary
FieldDetail
CompanyElectromed, Inc. (ELMD)
Form TypeDEF 14A
Filed DateSep 30, 2025
Risk Levellow
Pages16
Reading Time19 min
Sentimentneutral

Sentiment: neutral

Topics: Proxy Statement, Shareholder Meeting, Corporate Governance, Executive Compensation, Director Election, Auditor Ratification, Virtual Meeting

Related Tickers: ELMD

TL;DR

**ELMD's board is pushing for continuity with all proposals, including a 'one year' say-on-pay frequency, signaling stable governance ahead of their virtual shareholder meeting.**

AI Summary

Electromed, Inc. (ELMD) is holding its 2025 Annual Meeting of Shareholders virtually on November 14, 2025, at 8:00 a.m. Central Time. Shareholders will vote on four key proposals: the election of eight directors, the ratification of RSM US LLP as the independent auditor for fiscal year ending June 30, 2026, an advisory vote on executive compensation, and an advisory vote on the frequency of future executive compensation votes. The Board of Directors recommends voting FOR all director nominees, FOR the ratification of RSM US LLP, FOR the advisory approval of executive compensation, and FOR a ONE YEAR frequency for executive compensation votes. As of the September 17, 2025 record date, there are 8,376,147 outstanding shares eligible to vote. The company emphasizes strategic growth drivers including sales force expansion, increased brand awareness, market development, and best-in-class support, indicating a focus on expanding its SmartVest Airway Clearance System market presence.

Why It Matters

This DEF 14A filing outlines Electromed's governance and shareholder engagement for 2025, impacting investors by detailing the board's recommendations on key votes, including executive compensation and auditor ratification. The shift to a virtual meeting format, consistent since prior years, reflects a broader market trend towards accessibility but also limits direct in-person shareholder interaction. For employees, the executive compensation vote provides insight into leadership's reward structure, while customers and the broader market will observe the company's strategic growth drivers like sales force expansion and brand awareness, which could signal future product reach and competitive positioning against other medical device companies.

Risk Assessment

Risk Level: low — The filing is a standard DEF 14A proxy statement, primarily detailing procedural information for the upcoming annual meeting on November 14, 2025. It does not disclose new financial risks, operational challenges, or significant changes in business strategy. The proposals are routine governance matters, such as director elections and auditor ratification, which typically present low immediate risk to investors.

Analyst Insight

Investors should review the executive compensation details when they become available to ensure alignment with performance and consider the board's recommendation for a 'one year' frequency for future advisory votes on executive compensation. Participate in the virtual meeting on November 14, 2025, to exercise voting rights on the election of eight directors and other proposals.

Financial Highlights

debt To Equity
X.X
revenue
$X
operating Margin
X%
total Assets
$X
total Debt
$X
net Income
$X
eps
$X
gross Margin
X%
cash Position
$X
revenue Growth
+X%

Key Numbers

  • 8 — Number of directors (Proposed number of directors to be elected)
  • 2025-11-14 — Annual Meeting Date (Date of the virtual Annual Meeting of Shareholders)
  • 8:00 a.m. CST — Annual Meeting Time (Start time of the virtual Annual Meeting)
  • 2025-09-17 — Record Date (Date for determining shareholders entitled to vote)
  • 8,376,147 — Outstanding shares of common stock (Number of shares eligible to vote as of the record date)
  • 4,188,074 — Shares for quorum (Minimum number of shares required to constitute a quorum)
  • 2026-06-02 — Shareholder proposal deadline (Deadline for inclusion in 2026 proxy materials)
  • 2026-08-16 — Director nomination deadline (Latest date for director nominations for 2026 Annual Meeting)
  • 1 — Recommended frequency for executive compensation votes (Board's recommendation for 'say-on-pay' frequency (one year))

Key Players & Entities

  • Electromed, Inc. (company) — Registrant and issuer of the DEF 14A filing
  • RSM US LLP (company) — Independent registered public accounting firm for fiscal year ending June 30, 2026
  • James L. Cunniff (person) — Designated proxy for voting shares
  • Bradley M. Nagel (person) — Designated proxy for voting shares
  • Securities and Exchange Commission (regulator) — Regulatory body overseeing the filing
  • Broadridge Financial Solutions (company) — Agent tabulating votes for the Annual Meeting
  • Board of Directors (person) — Recommends votes on all proposals
  • Personnel and Compensation Committee (person) — Evaluates shareholder concerns regarding executive compensation
  • Nominating and Governance Committee (person) — Recommends director nominations

FAQ

When is Electromed's 2025 Annual Meeting of Shareholders?

Electromed, Inc.'s 2025 Annual Meeting of Shareholders will be held on Friday, November 14, 2025, at 8:00 a.m. Central Time, as a completely virtual meeting accessible via www.virtualshareholdermeeting.com/ELMD2025.

What are the key proposals Electromed shareholders will vote on?

Shareholders will vote on four proposals: the election of eight directors, ratification of RSM US LLP as the independent auditor for fiscal year ending June 30, 2026, an advisory vote on executive compensation, and an advisory vote on the frequency of future executive compensation votes.

What is the Board of Directors' recommendation for the executive compensation vote at Electromed?

The Board of Directors recommends a vote FOR the approval, on a non-binding and advisory basis, of Electromed's executive compensation as set forth in the proxy statement.

How many shares of Electromed common stock are eligible to vote at the Annual Meeting?

As of the record date, September 17, 2025, there were 8,376,147 outstanding shares of Electromed common stock, each eligible to cast one vote on matters presented at the Annual Meeting.

Why is Electromed holding a virtual Annual Meeting?

Electromed believes that a virtual meeting provides greater access to shareholders who wish to attend, ensuring all attendees have the same rights and opportunities to participate as they would at an in-person meeting, including asking questions.

What is the deadline for submitting shareholder proposals for Electromed's 2026 Annual Meeting?

To be considered for inclusion in Electromed's proxy materials for the 2026 Annual Meeting, shareholder proposals must be submitted in writing no later than June 2, 2026.

Who is Electromed's independent registered public accounting firm for fiscal year 2026?

RSM US LLP has been appointed as Electromed's independent registered public accounting firm for its fiscal year ending June 30, 2026, subject to shareholder ratification at the Annual Meeting.

What is the effect of abstentions on Electromed's proposals 2 and 3?

If a shareholder abstains from voting on proposals 2 (auditor ratification) or 3 (executive compensation), their shares will be deemed present but will not be counted as voting in favor, which will have the same effect as a vote AGAINST the proposal.

What are Electromed's strategic growth drivers mentioned in the filing?

Electromed highlights strategic growth drivers including sales force expansion, increased brand awareness, market development, and best-in-class support, focusing on its SmartVest Airway Clearance System.

Who are the designated proxies authorized to vote shares on behalf of Electromed shareholders?

James L. Cunniff and Bradley M. Nagel are the designated proxies authorized to vote shares of common stock at the Annual Meeting on behalf of Electromed shareholders.

Industry Context

Electromed focuses on the respiratory care market with its SmartVest Airway Clearance System. The company's strategy involves expanding its sales force, increasing brand awareness, developing new markets, and providing superior customer support to drive growth in this competitive sector.

Regulatory Implications

As a medical device company, Electromed is subject to stringent regulatory oversight from bodies like the FDA, impacting product development, manufacturing, and marketing. Compliance with evolving healthcare regulations and data privacy laws is crucial for continued operations and market access.

What Investors Should Do

  1. Review director nominees and vote FOR their election.
  2. Vote FOR the ratification of RSM US LLP as the independent auditor.
  3. Vote FOR the advisory resolution on executive compensation.
  4. Vote FOR a ONE YEAR frequency for future advisory votes on executive compensation.

Key Dates

  • 2025-11-14: Electromed, Inc. 2025 Annual Meeting of Shareholders — Shareholders will vote on key proposals including director elections, auditor ratification, and executive compensation.
  • 2025-09-17: Record Date for Annual Meeting — Determined the 8,376,147 shareholders eligible to vote at the Annual Meeting.

Glossary

Proxy Statement (DEF 14A)
A document filed with the SEC by a company that provides shareholders with information about matters to be voted on at an annual or special meeting. (This document outlines the agenda for Electromed's 2025 Annual Meeting and provides details on proposals and board recommendations.)
Record Date
A specific date set by a company to determine which shareholders are eligible to vote at a shareholder meeting. (Established as September 17, 2025, this date determined that 8,376,147 shares were eligible to vote.)
Virtual Meeting
A shareholder meeting conducted online, allowing remote participation via a webcast. (Electromed is holding its 2025 Annual Meeting virtually to enhance shareholder access and participation.)
Say-on-Pay
A shareholder advisory vote on executive compensation. (Shareholders will have an advisory vote on the compensation of Electromed's named executive officers.)

Year-Over-Year Comparison

This filing details the 2025 Annual Meeting agenda, including director elections, auditor ratification, and executive compensation votes. Specific comparative financial data or risk factor changes from the previous filing are not detailed within this excerpt, but the company's strategic focus on sales force expansion and market development suggests ongoing efforts to drive revenue growth.

Filing Stats: 4,764 words · 19 min read · ~16 pages · Grade level 13.2 · Accepted 2025-09-30 16:15:50

Filing Documents

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 24

Executive Compensation

Executive Compensation 25 Director Compensation 33 Equity Compensation Plan Information 34 Certain Relationships and Related-Party Transactions 35 Other Matters 36 Householding 36 Additional Information 36 QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING AND VOTING Q: Why did I receive this proxy statement? A: The Company is soliciting your proxy vote at the Annual Meeting because you were the owner of record of one or more shares of common stock of the Company at the close of business on September 17, 2025, the record date for the meeting, and are therefore entitled to vote at the Annual Meeting. Q: What is a proxy? A: A proxy is your legal designation of another person or persons (the "proxy" or "proxies," respectively) to vote on your behalf. By giving your proxy, you are authorizing James L. Cunniff and Bradley M. Nagel, the designated proxies, the authority to vote your shares of common stock at the Annual Meeting in the manner you indicate on your proxy card. If you authorize the proxies but do not give directions with respect to any nominee or other proposal, the proxies will vote your shares as recommended by the Board. The proxies are authorized to vote in their discretion (except as otherwise provided below) if other matters are properly submitted at the Annual Meeting, or any adjournments or postponements thereof. Q: When and where is the Annual Meeting? A: The Annual Meeting will be held on Friday, November 14, 2025. This year's Annual Meeting will be held as a completely "virtual meeting" of shareholders. You will be able to attend the Annual Meeting virtually, and vote and submit your questions during the Annual Meeting, via a live webcast by visiting www.virtualshareholdermeeting.com/ELMD2025 . The Annual Meeting will commence at 8:00 a.m. Central Time. Q: Why hold a virtual Annual Meeting? A: Consistent with recent years, this Annual Meeting will be held as a completely "virtual meeting" of shareholders. We believe tha

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.